Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

被引:61
作者
Poveda, E
Rodés, B
Labernardière, JL
Benito, JM
Toro, C
González-Lahoz, J
Faudon, JL
Clavel, F
Schapiro, J
Soriano, V
机构
[1] Hosp Carlos III Madrid, Dept Infect Dis, Madrid, Spain
[2] Hop Bichat Claude Bernard, INSERM, U552, Paris, France
[3] Viralliance SAS, Paris, France
[4] Stanford Univ, Palo Alto, CA 94304 USA
关键词
Enfuvirtide; T-20; drug resistance; immune activation; fusion inhibitors;
D O I
10.1002/jmv.20141
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Four heavily antiretroviral-experienced HIV-infected patients had significant plasma HIV-RNA reductions (>1 log) after beginning an Enfuvirtide (ENF)-based rescue regimen. However, all had viral rebound shortly thereafter, sustaining high levels of plasma viremia over 80 weeks. These patients developed rapidly genotypic and phenotypic resistance to ENF. Mutations within the HR1 env region were selected (N43D in three and G36V/D in one), resulting in high-level phenotypic resistance to ENF. Interestingly, two patients had a sustained CD4+ T-cell increase and two maintained stable CD4+ T-cell counts despite virologic failure under ENF. The possible mechanisms involved in this response were examined. Changes in virus tropism from R5 to R5/X4 were observed in two patients, in parallel with increases in ENF phenotypic resistance. Low levels of T-cell activation, T-cell turnover, and cytotoxic T lymphocyte (CTL) activity were found in all four patients. An overall increase in the proportion of viruses released from cells of the macrophage lineage was observed. In summary, single mutations at the HR1 env region result in significant loss of susceptibility to ENF. Despite virologic failure, these patients may maintain elevated CD4+ counts through a reduction in their overall immune activation. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 32 条
[1]  
[Anonymous], AIDS REV
[2]   Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors [J].
Benito, JM ;
López, M ;
Martín, JC ;
Lozano, S ;
Martínez, P ;
González-Lahoz, J ;
Soriano, V .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (18) :1379-1388
[3]   CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy [J].
Deeks, SG ;
Hoh, R ;
Grant, RM ;
Wrin, T ;
Barbour, JD ;
Narvaez, A ;
Cesar, D ;
Abe, K ;
Hanley, MB ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (03) :315-323
[4]   Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 [J].
Derdeyn, CA ;
Decker, JM ;
Sfakianos, JN ;
Wu, XY ;
O'Brien, WA ;
Ratner, L ;
Kappes, JC ;
Shaw, GM ;
Hunter, E .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8358-8367
[5]  
DEVAL J, 2003, ANTIVIR THER, V8, pS39
[6]   Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain [J].
Gallego, O ;
Ruíz, L ;
Vallejo, A ;
Clotet, B ;
Leal, M ;
Soriano, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3865-3866
[7]   Discordant responses during antiretroviral therapy role of immune activation and T cell redistribution rather than true CD4 T cell loss [J].
Hazenberg, MD ;
Otto, SA ;
Wit, FWNM ;
Lange, JMA ;
Hamann, D ;
Miedema, F .
AIDS, 2002, 16 (09) :1287-1289
[8]  
HEIL M, 2003, 10 C RETR OPP INF BO
[9]  
HEIL M, 2002, 9 C RETR OPP INF SEA
[10]   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
Clotet, B ;
Conway, B ;
Kuritzkes, DR ;
D'Aquila, RT ;
Demeter, LM ;
Hammer, SM ;
Johnson, VA ;
Loveday, C ;
Mellors, JW ;
Jacobsen, DM ;
Richman, DD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128